Home » Stocks » NVAX

Novavax, Inc. (NVAX)

Stock Price: $184.77 USD 2.05 (1.12%)
Updated Aug 3, 2021 12:57 PM EDT - Market open
Market Cap 13.54B
Revenue (ttm) 919.45M
Net Income (ttm) -615.11M
Shares Out 73.04M
EPS (ttm) -9.51
PE Ratio n/a
Forward PE 28.41
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $184.77
Previous Close $182.72
Change ($) 2.05
Change (%) 1.12%
Day's Open 183.04
Day's Range 178.95 - 186.35
Day's Volume 1,404,200
52-Week Range 76.59 - 331.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

On Novavax's (NVAX) upcoming second-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

1 hour ago - Zacks Investment Research

Novavax stock has declined by almost 12% over the last week (five trading days), compared to the S&P 500 which has remained roughly flat over the same period. The stock is also down by almost 16% over t...

2 hours ago - Forbes

Investors might hope that the spread of the Delta variant will boost NVAX stock, but a recent news release is likely to hinder progress. The post Covid-19 Vaccine Dose Delay Spells Even More Trouble for...

1 day ago - InvestorPlace

These players delivered triple- and quadruple-digit gains.

Other stocks mentioned: ARCT, BNTX, INO, MRNA, OCGN, PFE, VXRT
1 day ago - The Motley Fool

The latecomer could still carve out a spot for itself among the big vaccine makers.

2 days ago - The Motley Fool

Until Novavax secures FDA approval of its Covid-19 vaccine, investors should not buy NVAX stock, which has fallen 10% in recent days. The post Don't Buy Novavax Until Its Covid-19 Vaccine Wins FDA Appro...

4 days ago - InvestorPlace

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 days ago - Zacks Investment Research

After moving at less than warp speed, can this vaccine company catch up to the global opportunity?

5 days ago - The Motley Fool

You have the power to turn a negative event into something positive.

Other stocks mentioned: ABT
6 days ago - The Motley Fool

They will give us clues about when to expect billions in revenue.

6 days ago - The Motley Fool

There could be delays with the company supplying COVID-19 vaccine doses to Australia.

1 week ago - The Motley Fool

While NVAX stock may enjoy increased relevance on paper due to the delta variant, investors should think about the bigger picture. The post Novavax Stock May Not Get the Delta Varient Bump Investors Nee...

1 week ago - InvestorPlace

The answer is in the first two letters of the vaccine maker's name.

1 week ago - The Motley Fool

As the Dogecoin bubble bursts, these high-growth stocks are blossoming.

Other stocks mentioned: CRLBF, PUBM
1 week ago - The Motley Fool

Despite sizzling year-to-date gains, these stocks are surprisingly inexpensive.

Other stocks mentioned: BNTX, OMI
1 week ago - The Motley Fool

Yes, but it often doesn't have much to do with revenue.

Other stocks mentioned: CPRX
1 week ago - The Motley Fool

Concerns about the delta variant are rising.

Other stocks mentioned: BNTX, MRNA
1 week ago - The Motley Fool

Novavax is worth roughly 100% more. NVAX stock is worth $419 given its high efficacy, cheap price, easy storage and cheap valuation compared to Moderna.

1 week ago - InvestorPlace

Novavax stock has rallied by almost 12% over the last week (five trading days), compared to the S&P 500 which was down by almost 3% over the same period. The stock is also up by a solid 85% year-to-date.

1 week ago - Forbes

Novavax (NVAX) closed at $207.19 in the latest trading session, marking a -1.58% move from the prior day.

1 week ago - Zacks Investment Research

Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the...

Other stocks mentioned: IMNM, MRNA, NRBO, OCGN, QDEL
2 weeks ago - InvestorPlace

Stocks begin week with the market selling off; why? The post This Is Why Stocks Are Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other stocks mentioned: AEMD, AHPI, MTSL, OGEN
2 weeks ago - PennyStocks

Novavax, Inc. (NASDAQ: NVAX) shares rallied higher Monday after renewed COVID-19 concerns. The new Delta variant has been spreading and is a major concern with it recently becoming the dominant strain o...

2 weeks ago - Benzinga

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.

Other stocks mentioned: BNTX, CODX, MRNA, PFE, VXRT
2 weeks ago - The Motley Fool

NVAX stock has had a turbulent 2021, but with its Covid-19 vaccine expected to go into product in Q4, growth looms. The post Plenty of Upside Potential Looms Ahead of Novavax Stock's Bumpy Road appeared...

2 weeks ago - InvestorPlace

Catalysts for the shares are right around the corner.

2 weeks ago - The Motley Fool

In the latest trading session, Novavax (NVAX) closed at $179.14, marking a +0.75% move from the previous day.

2 weeks ago - Zacks Investment Research

Investors were increasingly confident that the company's COVID-19 vaccine would be successful.

2 weeks ago - The Motley Fool

Based on company forecasts, Wall Street estimates, and author guestimates, the top coronavirus vaccine developers will bring in billions of dollars in sales this year.

Other stocks mentioned: AZN, BNTX, JNJ, MRNA, PFE
3 weeks ago - The Motley Fool

Triple-digit revenue growth awaits this popular trio of companies next year.

Other stocks mentioned: BTC, MARA, NKLA
3 weeks ago - The Motley Fool

Novavax (NVAX) closed at $188.59 in the latest trading session, marking a -0.55% move from the prior day.

3 weeks ago - Zacks Investment Research

Investors appear to be worried about the impact of the delta variant.

3 weeks ago - The Motley Fool

COVID-19 concerns are driving the vaccine stocks higher.

Other stocks mentioned: MRNA
3 weeks ago - The Motley Fool

Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.

Other stocks mentioned: AZN, BNTX, JNJ, MRNA, PFE
3 weeks ago - Zacks Investment Research

The company finally got some good news about its vaccine production schedule.

3 weeks ago - The Motley Fool

Stock markets moved slightly higher despite general worries.

Other stocks mentioned: BNTX, INO, MRNA, OCGN
3 weeks ago - The Motley Fool

Novavax, Inc. (NASDAQ:NVAX) shares tumbled lower Wednesday after retail traders were able to push the stock lower. Vaccine stocks were very volatile today, and many are trading lower amid possible profi...

3 weeks ago - Benzinga

Today's significant selloff appears to be tied at least in part to some large stock sales made by the company's CEO earlier this month. The post NVAX Stock: One Big Reason Novavax Is Struggling Today ap...

3 weeks ago - InvestorPlace

Novavax published results of its U.S. phase 3 trials for its Covid-19 vaccine in mid-June, noting that the shot was over 90% effective overall and 100% effective against moderate and severe disease, rou...

3 weeks ago - Forbes

Novavax should take off as its successful Covid-19 vaccine spreads. NVAX stock is worth at least 50% more, given a mixture of analysts' estimates and comp analysis.

3 weeks ago - InvestorPlace

NVAX stock is beginning to look like all the good news is priced in. However, a successful Covid-19 vaccine may be a catalyst for other vaccines.

3 weeks ago - InvestorPlace

GAITHERSBURG, Md., July 6, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report ...

4 weeks ago - PRNewsWire

On June 14, Novavax announced that its Covid-19 vaccine, officially called "NVX-CoV2373," proved to be 93% effective against the Coronavirus and its variants in a phase 3 clinical trial. The vaccine was...

4 weeks ago - InvestorPlace

In the latest trading session, Novavax (NVAX) closed at $217.22, marking a +0.68% move from the previous day.

1 month ago - Zacks Investment Research

It involves producing a vaccine in great volume.

1 month ago - The Motley Fool

Value stocks have a knack for outperforming during the early stages of an economic recovery.

Other stocks mentioned: CMI, IBM
1 month ago - The Motley Fool

There's a case to be made that it is.

Other stocks mentioned: BNTX, JNJ, MRNA, PFE
1 month ago - The Motley Fool

Let's use recent efficacy data as a starting point.

Other stocks mentioned: MRNA, PFE
1 month ago - The Motley Fool

Wall Street expects gains in the coming year.

1 month ago - The Motley Fool

Major catalysts are on the horizon.

1 month ago - The Motley Fool

About NVAX

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate... [Read more...]

Industry
Biotechnology
IPO Date
Dec 5, 1995
CEO
Stanley Erck
Employees
792
Stock Exchange
NASDAQ
Ticker Symbol
NVAX
Full Company Profile

Financial Performance

In 2020, Novavax's revenue was $475.60 million, an increase of 2,448.48% compared to the previous year's $18.66 million. Losses were -$418.26 million, 215.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Novavax stock is "Buy." The 12-month stock price forecast is 271.75, which is an increase of 47.07% from the latest price.

Price Target
$271.75
(47.07% upside)
Analyst Consensus: Buy